Ocugen Inc. - Patient-Centric Biotechnology
At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. Our …
Press Releases - Ocugen, Inc.
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
OCU400 - Ocugen
Contact us at [email protected] Study title A Phase 3, Multi-Center, Randomized Study to Assess The Efficacy, Safety and Tolerability of Subretinal OCU400 Gene Therapy for …
About - Ocugen
About Ocugen OUR PEOPLE Our leaders have a proven track record of success across the healthcare industry—in biopharmaceutical research, commercialization, medicine, and …
Gene Therapies - Ocugen
Ocugen received Orphan Drug Designation from the FDA for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19 (RP19), and cone-rod …
Scientific Platforms - Ocugen
At Ocugen, we approach drug development with a sense of urgency, resolve, ingenuity, and boldness. We consider patients in everything we do. Courageous innovation means driving …
Contact - Ocugen
For investor-specific questions email [email protected] For clinical trial information email [email protected] If you are looking for healthcare advice or guidance, please …
Therapeutic Areas - Ocugen
Ocugen is developing a novel anti-viral mucosal vaccine targeting COVID-19. The intent is to provide protection against severe disease, increase durability and prevent transmission of viral …
Biologicals - Ocugen
OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like diabetic macular edema (DME), diabetic retinopathy (DR), and wet …
Our People - Ocugen
Arun Upadhyay, PhD, Chief Scientific Officer, and Head of Research, Development and Medical, drives Ocugen’s innovation and product development. He leads science and operations, …